Dongdong Wang

As a dedicated researcher in the field of "AI for Science," I am passionate about advancing the practical implementation of this paradigm to address "undruggable" targets. My work focuses on promoting a synergistic approach that combines Artificial Intelligence, Molecular Simulation, and Experimentation. I have spearheaded the development of the RiDYMO drug discovery platform, which has proven effective in targeting challenging proteins such as c-myc, β-catenin, and GPX4. RiDYMO is an AI for Science-driven hit discovery platform. By harnessing physics and artificial intelligence, we explore the vast chemical space, elucidate the dynamics of challenging targets, and rapidly deliver small molecules and macrocycles beyond the rule of five, ultimately addressing unmet medical needs. I am committed to leveraging these cutting-edge technologies to drive pharmaceutical innovation and make a meaningful impact on global health.